Last-Hope treatment offered for aggressive brain cancer patients
NCT ID NCT06404034
Summary
This program provided gallium maltolate (GaM) capsules to adults with glioblastoma that had returned or stopped responding to standard treatments. Patients took one capsule daily by mouth at home for 28-day cycles. The goal was to offer a potential treatment option when no other approved therapies were available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Partners of Nebraska
Lincoln, Nebraska, 68516, United States
-
Northwell Health
New York, New York, 10075, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.